drugset

drugset / Trial / NCT06639295

A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps

NCT06639295 ↗

Phase 3 Active not recruiting 243 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the effect and safety of 611 in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Timeline

Start: 2024-11-22
Primary completion: 2025-12
Completion: 2026-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	611	Unknown	2 ml	Subcutaneous

Indications